Fortunato Ciardiello, MD, PhD, University of Campania

home / authors / fortunato-ciardiello,-md,-phd,-university-of-campania

Articles

Future Directions in Later Line Therapy for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Key Trials in mCRC: I/O Combination Therapies

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Role of I/O Combination Therapies in mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Using I/O in MSI-H Tumors in mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Sequencing in mCRC: Later-Line Therapies

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

$Therapeutic Agents in Relapsed/Refractory mCRC$

Therapeutic Agents in Relapsed/Refractory mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

CORRECT, RECOURSE, and ReDOS Trials in mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Later Lines of Therapy for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Second-Line Treatment for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Initiating Therapy for mCRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Continuum of Care for Metastatic CRC

Fortunato Ciardiello, MD, PhD, University of Campania;Axel Grothey, MD, West Cancer Center & Research Institute;Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

June 29th 2020

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512